Impact of Early Rejection Treatment on Infection Development in Kidney Transplant Recipients: A Propensity Analysis
Table 1
Demographics and clinical characteristics for control and case cohorts.
Case (n = 185)
Control (n = 185)
value
Age at transplant
0.6571
Mean (SD)
53.6 (14.0)
53.0 (14.6)
Male
0.6752
No
82 (44.3%)
78 (42.2%)
Yes
103 (55.7%)
107 (57.8%)
Diabetes
0.5962
No
108 (58.4%)
113 (61.1%)
Yes
77 (41.6%)
72 (38.9%)
BMI
0.4281
Mean (SD)
28.6 (5.9)
28.1 (5.5)
Txp year
0.8782
2014
31 (16.8%)
33 (17.8%)
2015
24 (13.0%)
26 (14.1%)
2016
23 (12.4%)
18 (9.7%)
2017
26 (14.1%)
21 (11.4%)
2018
35 (18.9%)
33 (17.8%)
2019
35 (18.9%)
44 (23.8%)
2020
11 (5.9%)
10 (5.4%)
Deceased donor
0.2022
No
34 (18.4%)
44 (23.8%)
Yes
151 (81.6%)
141 (76.2%)
Induction therapy
0.9482
Basiliximab
67 (36.2%)
69 (37.3%)
Alemtuzumab
104 (56.2%)
101 (54.6%)
Antithymocyte globulin
14 (7.6%)
15 (8.1%)
Steroid avoidance
0.7462
No
119 (64.3%)
116 (62.7%)
Yes
66 (35.7%)
69 (37.3%)
eGFR at 4 months
0.9351
Mean (SD)
49.7 (20.1)
49.5 (19.3)
The baseline demographics and clinical characteristics for both cohorts, after matching. There were no significant differences between the cohorts. Analysis completed using 1two-sample t-test and 2Pearson’s chi-squared test.